Urine and blood biomarkers correlate with rate of eGFR decline in Alport syndrome: The ATHENA Study. Urine and blood biomarkers correlate with rate of eGFR decline in Alport syndrome: The ATHENA Study Post navigation Previous: Efficacy of RGLS4326 in Human Primary 3D-Cyst Cultures Derived from Autosomal Dominant Polycystic Kidney Disease (ADPKD) DonorsNext: RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse Models
